Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer : the end of the debate
| Errataetall: |
CommentIn: Ann Oncol. 2022 Jun;33(6):658-659. - PMID 35306157 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 33(2022), 3 vom: 01. März, Seite 347-349 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Poggio, F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 07.07.2022 published: Print-Electronic CommentIn: Ann Oncol. 2022 Jun;33(6):658-659. - PMID 35306157 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2021.11.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33398126X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33398126X | ||
| 003 | DE-627 | ||
| 005 | 20231225222748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.11.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM33398126X | ||
| 035 | |a (NLM)34861375 | ||
| 035 | |a (PII)S0923-7534(21)04831-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Poggio, F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer |b the end of the debate |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 07.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Oncol. 2022 Jun;33(6):658-659. - PMID 35306157 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 700 | 1 | |a Tagliamento, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ceppi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Bruzzone, M |e verfasserin |4 aut | |
| 700 | 1 | |a Conte, B |e verfasserin |4 aut | |
| 700 | 1 | |a Fregatti, P |e verfasserin |4 aut | |
| 700 | 1 | |a Punie, K |e verfasserin |4 aut | |
| 700 | 1 | |a de Azambuja, E |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, L |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 33(2022), 3 vom: 01. März, Seite 347-349 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2022 |g number:3 |g day:01 |g month:03 |g pages:347-349 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2021.11.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2022 |e 3 |b 01 |c 03 |h 347-349 | ||